Macrogen becomes the first company to bring NovaSeq X Plus to Korea, the first in Asia

Macrogen, a global company specializing in genome sequencing, completed the installation of NovaseqX Plus on March 6, the first company to adopt NovaSeq X Plus, a high-precision whole genome sequencing system developed by US-d Illumina in Korea.

With NovaSeq X Plus fully installed, Macrogen will be able to operate with the most innovative system. Following this first installation at the Korean Genome Center, Macrogen will proceed to install four more units at its global subsidiaries, including in Japan and Europe, as well as at Psomagen, its US partner company, for a total of five. NovaSeq X Plus equipment in their labs later this year.

Macrogen plans to dramatically increase its throughput with the help of NovaSeq X Plus, which will serve as a growth engine for its sequencing business.

The NovaSeq X machine offers a dramatic improvement over existing sequencers in terms of speed, scale, accuracy, and sustainability, it also offers significant improvement in the following areas:

• 2 times more speed and up to 3 times more precision.
• 2.5 times more performance, thanks to the highest resolution optics and ultra-high density flow cells.
• Fully automated, high-precision secondary analysis with 5x lossless data compression.
•  Reduction of packaging waste with more thermostable reagents.

The revolutionary technology is expected to offer a major inflection point in the advancement of genomic medicine, including cancer treatments and genetic disease research, promoting an improvement in the quality of human health.

*Photo: Rob McBride, CEO of Illumina Korea, and Changhun Kim, President of Macrogen.